Kenneth C. Anderson

Kenneth C. Anderson is the most influential researcher in multiple myeloma therapeutics, having transformed patient outcomes through systematic development of novel drug classes. His laboratory validated BCMA as the ideal myeloma target (Blood 2014), directly enabling all BCMA-targeted therapies including bispecific antibodies and CAR-T cells. His co-development of proteasome inhibitors (bortezomib, NEJM 2003) established a new drug class now standard in myeloma. Elected to the National Academy of Medicine in 2010, he has received the ASCO Karnofsky Award, ASH Dameshek Prize, and AACR Burchenal Award. With 2,330 publications and 216,202 citations (D-index 229), Anderson ranks #55 in Medicine globally. He served as President of both ASH and the International Myeloma Society.

Kenneth C. Anderson博士是多发性骨髓瘤治疗领域最具影响力的研究者，通过系统开发新型药物类别彻底改变了患者预后。他的实验室验证了BCMA作为理想骨髓瘤靶点（Blood 2014），直接促成了包括双特异性抗体和CAR-T细胞在内的所有BCMA靶向疗法。他共同开发蛋白酶体抑制剂（硼替佐米，NEJM 2003）建立了现已成为骨髓瘤标准的新药物类别。2010年当选美国国家医学院院士，他获得ASCO Karnofsky奖、ASH Dameshek奖和AACR Burchenal奖。凭借2,330篇出版物和216,202次引用（D指数229），Anderson在医学领域全球排名第55。他曾任ASH和国际骨髓瘤学会主席。